Unlocking potential in Life Sciences: collaborative research between Academia and Industry in Europe
HUMAN TECHNOPOLE V.le Rita Levi-Montalcini, 1 - 20157, MILANO
Daniela Bellomo
OSPEDALE SAN RAFFAELE, Director Business Development and Technology Transfer Division
Fabrizio Conicella
CHIESI FARMACEUTICI, Head of Open Innovation & Competence
Alessandro Curioni
IBM RESEARCH – ZURICH, IBM fellow, VP Europe and Africa and Director
Bert Klebl
LEAD DISCOVERY CENTER, Managing Director and Chief Scientific Officer
Marica Nobile
FEDERCHIMICA ASSOBIOTEC, Director
Corrado Panzeri
THE EUROPEAN HOUSE - AMBROSETTI, Partner e Responsabile Innovation & Technology Hub
Francesca Pasinelli
FONDAZIONE TELETHON, Deputy Board Member
Fabio Terragni
FONDAZIONE HUMAN TECHNOPOLE, Member of the Management Committee delegate for technology transfer
Gianmario Verona
FONDAZIONE HUMAN TECHNOPOLE, President
Marino Zerial
FONDAZIONE HUMAN TECHNOPOLE, Director
The process of technology transfer in the Life Sciences aims to advance early scientific inventions and discoveries to the next generation of diagnostics, therapies, services, and enterprises. Because of its intrinsic attitude to risk, hypothesis-driven research, and data sharing, academia produces a large amount of highly valuable discoveries and inventions that, regrettably, do not always translate into therapies and products beneficial for society. Indeed, the journey from academic research to patients requires competencies, know-how, and access to considerable scientific, human, and economic resources. Academia spin-offs and start-ups often lack the resources and know-how to tackle these challenges. On the other hand, the industry has been thriving in delivering breakthrough therapies and diagnostic tools to patients while not being as effective as academia in producing breakthrough scientific discoveries. Collaboration between academia and industry is essential to unlock the full potential of both worlds, and Europe hosts several examples of such collaborations.
With this in mind, we would like to gather some of the key players in the Italian Life Science ecosystem to discuss such European examples and join efforts to build a model for Italy.
